West Pharmaceutical Services (WST) EPS (Basic) (2009 - 2026)

West Pharmaceutical Services (WST) has reported EPS (Basic) for 18 consecutive years, with $2.09 the latest figure, recorded in Q2 2026.

• Quarterly EPS (Basic) rose 18.95% year-over-year to $2.09 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.76 (up 18.35% YoY) and the FY2025 annual result came in at $6.63, up 1.24% from the prior year.
• EPS (Basic) grew to $2.09 in Q2 2026 per WST's latest filing, from $1.88 in the prior quarter.
• Over the last five years, EPS (Basic) for WST reached as high as $2.46 in Q2 2022 and fell as low as $1.19 in Q1 2025.
• A 5-year average of $1.8 and a median of $1.8 in 2023 frame the typical range for EPS (Basic).
• Annual changes were most pronounced in 2022 — EPS (Basic) tumbled 32.43% — and 2026, when it surged 57.8%.
• Year by year, EPS (Basic) stood at $1.34 in 2022, then surged by 34.15% to $1.8 in 2023, then declined by 2.48% to $1.75 in 2024, then climbed by 1.05% to $1.77 in 2025, then increased by 17.81% to $2.09 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $2.09, $1.88, and $1.77 for Q2 2026, Q1 2026, and Q4 2025 respectively.